PeptideFactSheetsAn independent reference
Menu

Phenyl-substituted racetam · Fact sheet

Phenylpiracetam

Also known as Fonturacetam · Carphedon

Phenylpiracetam is a phenyl-substituted racetam discussed for stimulation and cognition. The cited primary work on individual enantiomers is in mice; it does not establish a safe human performance regimen.

Not FDA approvedLimited or unclear evidence
Brain, mood & sleep

What is Phenylpiracetam?

R- and S-phenylpiracetam are mirror-image forms whose actions can differ. A racemic product contains both.

A finding with one enantiomer cannot automatically describe a mixed product.

Benefits & claims

Readers encounter Phenylpiracetam in discussions of cognition, mood or mental fatigue. The relevant study population and outcome determine whether those claims are supported.

What the evidence supports

  • R-phenylpiracetam was studied in experimental inflammation models in male mice.
  • S-phenylpiracetam affected mouse weight gain without the same locomotor pattern attributed to related forms.
  • These experiments cannot establish sustained human attention, weight loss or safe stimulation.
Research areas
  • Cognition and memory
  • Neurologic or psychiatric research

Dosage & frequency

No established human regimen

The reviewed sources do not establish a human treatment amount or frequency for Phenylpiracetam. Animal and laboratory exposures are not human regimens.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • A finding with one enantiomer cannot automatically describe a mixed product.

Interactions & precautions

  • The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.

What is still unresolved

  • Reproducible benefit on everyday function in the intended population
  • Long-term safety and clinically important interactions
  • Equivalence of nonstandard products to research formulations
Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice. S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity. Five Unapproved Drugs Found in Cognitive Enhancement Supplements. FDA warning letter: unapproved nootropic claims

Side effects & risks

  • Human psychiatric, cardiovascular and long-term safety are insufficiently defined by these sources.
  • Supplement testing has identified unapproved drugs and labeling problems; a name on a label does not confirm exposure.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Limited or unclear evidence

Mouse mechanism studies and supplement analyses do not establish reliable clinical efficacy or product equivalence.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 2 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

More focus and exercise stamina, with headaches and insomnia

An author described improved focus, mood, energy and running stamina over six months of intermittent phenylpiracetam use. They also described headaches, insomnia and jitteriness, especially alongside more coffee.

Reported use in this account

Product
Phenylpiracetam
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Six months of intermittent use

Other exposures described: Coffee; Other supplements described in the source; combinations varied

The post mixes first-person experience with unsupported safety claims and advice; only the personal observations are summarized. Multiple other supplements and caffeine complicate attribution.

Read the original account

Approval status

Phenylpiracetam is not an FDA-approved treatment for the cognitive or mood uses discussed here. Regional use, historical trials and online availability are separate from U.S. drug approval.

No FDA-approved product for this entry

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Reproducible benefit on everyday function in the intended population
  • Long-term safety and clinically important interactions
  • Equivalence of nonstandard products to research formulations

Summary

These experiments cannot establish sustained human attention, weight loss or safe stimulation.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  3. pubmedFive Unapproved Drugs Found in Cognitive Enhancement Supplements.

    Laboratory analysis of cognitive-enhancement supplements.

  4. fdaFDA warning letter: unapproved nootropic claims

    FDA identifies unapproved drug claims for named nootropics; this is an enforcement letter, not efficacy evidence.

How we assess sources · Suggest a correction